The Latest SPAC News and Rumors: August 1, 2022
by Marlena Haddad on 2022-08-01 at 12:29pm

 


Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. 

Latest SPAC News: Nikola buys Romeo Power for 11% of SPAC valuation, Morgan Stanley’s top SPAC banker exits for Elliott, and SeaStar Medical reports successful treatment 


Nikola Buys Romeo Power for 11% of Battery Maker’s SPAC Valuation 

Nikola Corp. (NASDAQ:NKLA) will acquire Romeo Power Inc. (NYSE:RMO) for a sliver of what the battery maker was worth when it merged with a special purpose acquisition company less than two years ago.

The all-stock transaction between two manufacturers that went public via blank-check deals in 2020 values Romeo Power at about $144 million, according to a statement Monday. That’s only about 11% of the roughly $1.33 billion value at which California-based Romeo Power agreed to merge with a SPAC.

READ

Morgan Stanley SPAC Banker Bennett Schachter Exits for Elliott

Bennett Schachter, the top SPAC banker at Morgan Stanley and its global head of alternative capital, is leaving for a role at Elliott Investment Management, according to people with knowledge of the matter.

Schachter, who joined the New York-based bank in 2019 after more than two decades at Goldman Sachs Group Inc., is set to join the Paul Singer-led hedge fund later this year, said the people, asking not to be identified as the move isn’t yet public.

READ

SeaStar Medical Reports First Successful Treatment of Pediatric Patient with Hemophagocytic Lymphohistiocytosis and Multi-Organ Failure with its SCD

SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO), a special purpose acquisition company, today announced that SeaStar Medical’s novel Selective Cytopheretic Device (SCD) was successfully used in a pediatric patient with hemophagocytic lymphohistiocytosis (HLH), a dysregulated immune disorder in children associated with Epstein Barr virus (EBV), the virus that causes mononucleosis.

In its most severe form, HLH presents with signs and symptoms of hyperinflammation that can progress to multiorgan failure with life-threatening consequences. This is the first case of SCD therapy in a pediatric patient with HLH and multiorgan failure.

READ


Recent Posts
by Nicholas Alan Clayton on 2024-09-13 at 12:01pm

Alpha Star (NASDAQ:ALSA) has entered into a definitive agreement to combine with fintech firm XDATA at an equity value of $180 million. Tallinn, Estonia-based XData provides payment software and digital banking systems for business clients. The combined company is expected to trade on the Nasdaq once the deal is completed in late 2024. Transaction Overview...

by Nicholas Alan Clayton on 2024-09-13 at 8:10am

At the SPAC of Dawn The market shifted this week on the see-saw of the US election prospects, but, beyond the policies at play, another impact the election could have on the SPAC market is the potential for a fair amount of people movement. Many of the biggest names in SPACland have been bundling donations...

by Nicholas Alan Clayton on 2024-09-12 at 8:24am

At the SPAC of Dawn After what appeared to a pause in activity around the presidential debate, Southport (OTC:PORT) and Future Vision II (NASDAQ:FVNNU) broke the seal yesterday on both new business combinations and IPOs, respectively. Two SPACs are about to come off of the board as well, however, as 99 Acquisition Group (NASDAQ:NNAG) has...

by Kristi Marvin on 2024-09-11 at 5:27pm

Future Vision II Acquisition Corp. announced the pricing of its $50 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “FVNNU”, Friday, September 12, 2024. The new SPAC intends to focus its search on businesses within the technology, media, and telecommunications sector. Future Vision II’s sponsor team is...

by Nicholas Alan Clayton on 2024-09-11 at 12:38pm

Southport (OTC:PORT) has entered into a definitive agreement to combine with Angel Studios at a pro forma enterprise value of $1.56 billion. Angel Studios produces film and TV content for both streaming and theatrical releases. The combined company is expected to trade on the NYSE or Nasdaq under the symbol “AGSD” once the deal is...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved